2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Serologic Tests, Treatment Considerations, Supportive Care, Non-Biological Therapies, Anticoagulant Drugs, Coagulant Drugs, Women’s Health, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Value, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Inherited Marrow Failure Syndromes, Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Metabolic Disorders, Iron Deficiency, Research, Clinical Research, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Pediatric
PAPER

6151 Hospitalization cost avoidance and economic impact of outpatient-only bispecific T-cell engager initiation in community oncology

Maya Nicole Birhiray, M.S., Brian Mulherin, MD2, Brooke Peters, PharmD, BCOP3, Manale Maksour, PharmD, BCOP, BCPS4, Cassandra Perkey, PharmD, BCOP5, Nicole McMullen, PharmD, BCOP6, Robert Carr, PharmD, BCOP7, Melody Chang, RPh, MBA, BCOP8, Ruemu Ejedafeta Birhiray, MD9
1 Indiana University School of Medicine, Indianapolis, Indiana, United States, Indy Hematology Education, Carmel, Indiana, United States
2 Hematology Oncology of Indiana, Indianapolis, United States
3 American Oncology Network, Fort Myers, United States
4 American Oncology Network, Fort Myers, United States
5 American Oncology Network, Fort Myers, United States
6 American Oncology Network, Fort Myers, United States
7 American Oncology Network, Fort Myers, United States
8 American Oncology Network, Fort Myers, United States
9 American Oncology Network, Fort Myers, United States

PURPOSE: Bispecific T-cell engager (TCE) step-up dosing designed to mitigate adverse reactions in the treatment multiple myeloma and lymphomas usually requires inpatient hospitalization or prolonged observation because of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). As result multiple strategies for outpatient initiation of therapy including intensive monitoring and prophylactic administration of tociluzumab have been employed. However, although outpatient initiation may reduce hospital use, its economic impact is not well characterized, particularly in community oncology settings. Therefore, we estimated hospitalization cost avoidance and budget impact associated with an outpatient-only TCE pathway in a community oncology network. 

METHODS: We performed a retrospective review of patients who initiated any bispecific TCE for multiple myeloma or lymphoma through an outpatient-only pathway developed for American Oncology Network practices. The pathway used standardized toxicity monitoring, protocol-directed supportive care, and prophylactic tocilizumab at physician discretion. Outcomes included CRS, ICANS, and CRS/ICANS-related hospitalization within 30 days. A modeled budget impact analysis was conducted using U.S. commercial payer reporting for general hospitalizations. The comparator assumed one ≥24-hour hospitalization for each patient during step-up dosing, reflecting the historical inpatient initiation strategy. The base case used $21,400 per hospitalization and $2,600 for prophylactic tocilizumab acquisition and administration using data from public sources. Costs were compared for the observed outpatient cohort versus the modeled inpatient strategy. Net savings, savings per patient, hospitalizations prevented, and return on investment (ROI) were calculated. These assumptions do not include the multiday hospitalization required per label for some the products and when hospitalization may not be required for others. 

RESULTS: Thirty-seven patients with multiple myeloma, follicular lymphoma, or diffuse large B-cell lymphoma received teclistamab, talquetamab, elranatamab, linvoseltamab, mosunetuzumab, or epcoritamab. Prophylactic tocilizumab was administered to 27 patients (73.0%). CRS occurred in 5 patients (13.5%) and ICANS in 2 (5.4%); all events were grade 1. Three patients (8.1%) required CRS/ICANS-related hospitalization within 30 days. Compared with the modeled inpatient strategy of 37 admissions, the observed pathway resulted in 3 admissions, corresponding to 34 hospitalizations prevented and a 91.9% reduction in hospitalization. Modeled inpatient hospitalization costs were $791,800 versus $64,200 for observed admissions. Prophylactic tocilizumab costs were $70,200, yielding a total modeled outpatient strategy cost of $134,400, excluding other outpatient supportive-care costs. Estimated net savings were $657,400, or $17,768 per patient. The estimated ROI on prophylactic tocilizumab expenditure was 936%, equivalent to $9.36 in net savings per $1 spent. 

CONCLUSIONS: Outpatient-only bispecific TCE initiation in community oncology was associated with infrequent hospitalization and a substantial projected cost avoidance compared with a modeled routine inpatient strategy. Despite, including prophylactic tocilizumab costs, the pathway driven strategy generated estimated net savings exceeding $650,000 for 37 patients. Because the base case conservatively assumed only one 24-hour hospitalization per patient, regimens requiring multi-day hospitalization would be expected to yield greater savings, potentially several-fold higher depending on length of stay and payer reimbursement and medical resource utilization. Similarly, regimens not requiring hospitalization may not result in net savings. Community-based outpatient TCE delivery may also potentially reduce barriers created by hospital admission or referral to distant academic centers, including treatment delays, travel burden, care fragmentation, and limited access to specialized therapies. These findings support prospective validation using actual payer-allowed amounts, complete outpatient resource costs, and matched inpatient comparators including hospital resource utilization to define the economic and access value of community-based outpatient TCE initiation. 

Maya Nicole Birhiray, M.S.: No relevant conflicts of interest to declare.